What happened

PAVmed (NASDAQ:PAVM) was a winner on Wednesday. The medical device maker's stock rose by over 12% on the back of a key appointment to the board of directors of its most important subsidiary.

So what

That appointment is of Stanley Lapidus, the founder and onetime CEO of DNA-based diagnostics company Exact Sciences (NASDAQ:EXAS). Lapidus has been tapped to be vice chairman of the board of Lucid Diagnostics, the home of PAVmed's core suite of cancer testing products.

Gloved and masked medical researchers using microscopes in their work.

Image source: Getty Images.

The Exact Sciences leading light and healthcare industry veteran is no stranger to PAVmed. Last month, the latter company announced it had brought Lapidus on to Lucid Diagnostics as a strategic advisor. At the time, PAVmed said that he would assist it with its activities in the commercial, capital markets, and regulatory realms.

As for this latest appointment, PAVmed quoted its CEO Lishan Aklog as saying that "Stan has long been a leading figure in the medical diagnostics industry and is one of its most accomplished innovators in the early detection of cancer -- innovations which have prevented countless deaths from cervical and colon cancer."

Now what

PAVmed did not specify how much Lapidus will be paid for his labors at Lucid Diagnostics. Regardless, the company's deepening involvement with a respected veteran holding deep and wide experience in its area of specialization feels like quite a "get." It promises to not only lock in Lapidus' knowledge of cancer diagnosis, but also bumps up the company's own profile and visibility by secondary association with the well-known Exact Sciences.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.